Drugmaker Eli Lilly and Co. Announces $3.5 Billion Facility in Pennsylvania
Eli Lilly plans to construct a $3.5 billion manufacturing facility in Fogelsville, Pennsylvania, to expand its production of obesity and diabetes treatments, including injectable drugs like retatrutide. This initiative is part of a broader domestic expansion, with new plants also in Texas, Virginia, and Alabama. The company reported a record third-quarter profit of $5.58 billion, driven by strong sales of its weight-loss and diabetes drugs, Zepbound and Mounjaro. Construction is set to begin this year and conclude by 2031.
